Premium
Histochemical assay of estrogen and progesterone receptors in breast cancer: Correlation with biochemical assays and patients' response to endocrine therapies
Author(s) -
Pertschuk Louis P.,
Tobin Ellis H.,
Gaetjens Eric,
Carter Anne C.,
Degenshein George A.,
Bloom Norman D.,
Brigati David J.
Publication year - 1980
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19801215)46:12+<2896::aid-cncr2820461431>3.0.co;2-9
Subject(s) - endocrine system , medicine , estrogen receptor , estrogen , progesterone receptor , endocrinology , breast cancer , receptor , mammary gland , cancer , metastatic breast cancer , fluorescein isothiocyanate , hormone , physics , quantum mechanics , fluorescence
Estrogen (ER) and progesterone (PgR) receptors were assayed by histochemistry in primary, recurrent, and metastatic breast cancer. Ligand‐conjugates composed of 17β‐estradiol and 11α‐hydroxyprogesterone covalently linked to bovine serum albumin and labelled with fluorescin isothiocyanate were employed. Results were compared with those of conventional biochemical receptor assays and correlated for ER in 92% of 314 tumors and for PgR in 86% of 86 specimens. ER and PgR determinations by both assay systems were correlated with clinical response to various endocrine therapies in 40 women with Stage IV disease. The histochemical assay enabled successful prediction of response in 80% of cases including eight which could not be fully analyzed biochemically.